NR3C2 and COVID-19: Therapies which act on cardiac remodeling, such as angiotensin-converting enzyme inhibitors or mineralocorticoid receptor antagonists merit evaluation for myocardial protection in patients with or recovered from the acute phase of COVID-19 (37, 38).